P
Pamela Tan
Researcher at Alnylam Pharmaceuticals
Publications - 45
Citations - 1662
Pamela Tan is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Gene & Small interfering RNA. The author has an hindex of 9, co-authored 45 publications receiving 1570 citations. Previous affiliations of Pamela Tan include Hoffmann-La Roche & Medtronic plc.
Papers
More filters
Journal ArticleDOI
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky,Aldo Grefhorst,Norma N. Anderson,Timothy Racie,Birgit Bramlage,Akin Akinc,David Butler,Klaus Charisse,Robert Dorkin,Yupeng Fan,Christina Gamba-Vitalo,Philipp Hadwiger,Muthusamy Jayaraman,Matthias John,K. Narayanannair Jayaprakash,Martin Maier,Lubomir Nechev,Kallanthottathil G. Rajeev,Timothy Read,Ingo Röhl,Jürgen Soutschek,Pamela Tan,Jamie Wong,Gang Wang,Tracy Zimmermann,Antonin de Fougerolles,Hans-Peter Vornlocher,Robert Langer,Daniel G. Anderson,Muthiah Manoharan,Victor Koteliansky,Jay D. Horton,Kevin Fitzgerald +32 more
TL;DR: PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc is validated, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.
Journal ArticleDOI
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Maria-del-Mar Inda,Rudy Bonavia,Akitake Mukasa,Akitake Mukasa,Yoshitaka Narita,Dinah W.Y. Sah,Scott R. VandenBerg,Cameron Brennan,Terrance Grant Johns,Robert Bachoo,Philipp Hadwiger,Pamela Tan,Ronald A. DePinho,Webster K. Cavenee,Frank B. Furnari +14 more
TL;DR: It is demonstrated that a paracrine mechanism driven by DeltaEGFR is the primary means for recruiting wtEGFR-expressing cells into accelerated proliferation in vivo, and support the view that a minor tumor cell population can potently drive accelerated growth of the entire tumor mass, and thereby actively maintain tumor cell heterogeneity within a tumor mass.
Patent
Compositions and methods for inhibiting expression of the PCSK9 gene
Pamela Tan,Birgit Bramlage,Maria Frank-Kamenetsky,Kevin Fitzgerald,Akin Akinc,Victor Kotelianski +5 more
TL;DR: In this paper, double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene were described. And methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS 1 were presented.
Patent
Compositions and methods for inhibiting expression of Huntingtin gene
Dinah Wen-Yee Sah,Philipp Hadwiger,Ingo Roehl,Birgit Bramlage,Pamela Tan,Hans-Peter Vornlocher,David Bumcrot +6 more
TL;DR: In this article, a double-stranded ribonucleic acid (dsRNA) was used for inhibiting the 5 expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene.